Impact of treatment with high-concentration capsaicin (8%) (QTZ) topical system on sensory testing in patients living with painful diabetic peripheral neuropathy of the feet: A post-hoc analysis of the PACE trial

For US healthcare professionals only

The purpose of this Averitas Pharma website is to provide educational information to US healthcare professionals only.
The content is not intended as promotion of medical products or as medical advice. Decisions regarding patient care are
the responsibility of healthcare professionals, guided by their expertise, licensure, and understanding of each
patient's unique needs. The content presented may include information pertaining to products or uses that have not
received approval form the US Food and Drug administration. Averitas Pharma does not recommend the use of its products
outside the approved prescribing information. For full prescribing information, including indications,
contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. All images
on this site are for illustrative purposes only and may include actors.